A multi-centre, general practice assessment of a timolol/bendrofluazide combination ('Prestim') in the treatment of mild to moderate hypertension
A fixed dose combination of 10 mg timolol and 2.5 mg bendrofluazide was evaluated in 1640 general practice patients with mild to moderate hypertension. This was an open study lasting 3 months with an initial 2-week placebo controlled run-in phase. Of the 1315 patients who were evaluable, 1169 (89%)...
| Veröffentlicht in: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1984), 10 vom: 20., Seite 650-6 |
|---|---|
| 1. Verfasser: | |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1984
|
| Zugriff auf das übergeordnete Werk: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Schlagworte: | Journal Article Antihypertensive Agents Drug Combinations Bendroflumethiazide 5Q52X6ICJI prestim 74335-22-1 Timolol 817W3C6175 |